Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
9.81
+0.34 (3.59%)
Apr 15, 2025, 4:00 PM EDT - Market closed
Amarin Corporation Revenue
In the year 2024, Amarin Corporation had annual revenue of $228.61M, down -25.51%. Amarin Corporation had revenue of $62.31M in the quarter ending December 31, 2024, a decrease of -16.61%.
Revenue (ttm)
$228.61M
Revenue Growth
-25.51%
P/S Ratio
0.88
Revenue / Employee
$831,324
Employees
275
Market Cap
203.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 228.61M | -78.30M | -25.51% |
| Dec 31, 2023 | 306.91M | -62.28M | -16.87% |
| Dec 31, 2022 | 369.19M | -213.99M | -36.69% |
| Dec 31, 2021 | 583.19M | -30.87M | -5.03% |
| Dec 31, 2020 | 614.06M | 184.31M | 42.89% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
AMRN News
- 1 day ago - Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday - Benzinga
- 6 days ago - Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change - GlobeNewsWire
- 8 days ago - Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors - GlobeNewsWire
- 27 days ago - Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance - Business Wire
- 27 days ago - New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo - GlobeNewsWire
- 4 weeks ago - Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering - GlobeNewsWire
- 7 weeks ago - Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025 - GlobeNewsWire